Basal-Bolus Insulin Cuts HbA1c 1.7 Points in Kolkata Kidney Transplant Study

A 24-week study of 112 kidney transplant recipients with pre-existing type 2 diabetes, published in Cureus this week, found that basal-bolus insulin therapy cut average HbA1c from 8.9% to 7.2% without measurable harm to the transplanted kidney.

The report comes from a single-center retrospective observational study at Narayana Health Rabindranath Tagore International Institute of Cardiac Sciences in Kolkata, whose ethics committee granted an exemption for retrospective data analysis in April 2025, Cureus reported.

A preliminary analysis of a subset of these patients had been presented earlier as an abstract at the 59th Annual Meeting of the European Association for the Study of Diabetes, held in Hamburg, Germany, from October 2 to 6, 2023.

Why it matters: diabetes drives roughly 25–30% of end-stage renal disease cases, and transplant recipients face a metabolic squeeze. Immunosuppressants such as tacrolimus impair pancreatic insulin synthesis and secretion and interfere with insulin’s peripheral action, while corticosteroids raise hepatic gluconeogenesis and reduce tissue sensitivity to insulin, according to the report’s cited literature.

Basal-Bolus Insulin Cuts HbA1c 1.7 Points in Kidney Transplant Patients

  • Kidney transplant patients with existing type 2 diabetes who started or continued basal-bolus insulin — a long-acting “background” insulin plus mealtime doses — brought their three-month average blood sugar down by 1.7 percentage points in 24 weeks.
  • Nearly half (45.5%) reached the standard target of HbA1c at or below 7%, and another 46.4% landed between 7% and 8%.
  • Kidney function markers (serum creatinine and eGFR) did not worsen over the six months, and average weight gain was a modest 1.24 kg.

The Numbers Behind the Regimen

The study tracked adults referred to an endocrinology outpatient department within two weeks of hospital discharge after living-donor kidney transplantation, between January 1, 2018 and November 30, 2019. Only patients without a history of graft rejection who were receiving corticosteroid therapy were included, Cureus reported.

Fasting plasma glucose fell from 237.9 to 122.3 mg/dL. Postprandial plasma glucose — the reading after meals — dropped from 342.2 to 173.0 mg/dL. HbA1c, the three-month average, fell from 8.9% to 7.2%.

Measure Baseline Week 24
HbA1c 8.9% 7.2%
Fasting plasma glucose 237.9 mg/dL 122.3 mg/dL
Postprandial plasma glucose 342.2 mg/dL 173.0 mg/dL

Weight gain differed numerically between basal insulin types — greater in the glargine group — but the difference was not statistically significant in the primary analysis (p = 0.061), a figure just past the conventional threshold of 0.05.

Degludec Versus Glargine: No Clear Winner

Patients received either insulin degludec or insulin glargine as the basal component, paired with regular human insulin or insulin aspart before meals. Degludec was preferred for its lower hypoglycemia risk, though affordability also influenced the choice; treatment was assigned as routine clinical care, not random allocation, Cureus reported.

Nocturnal hypoglycemia — low blood sugar between midnight and 5:59 a.m. — occurred in 4 of 60 patients (6.7%) on degludec and 7 of 52 (13.5%) on glargine. The difference was not statistically significant (p = 0.341). No significant differences emerged between basal types or between the two mealtime insulins on glycemic or renal outcomes.

Dosing followed a standard algorithm: basal insulin started at 10 units once daily in insulin-naïve patients, then titrated against the average of three consecutive pre-breakfast self-measured readings, targeting 80–130 mg/dL. A reading below 80 mg/dL triggered a 2-unit reduction; above 180 mg/dL, a 6-unit increase. Follow-up was weekly in the first month, then every two weeks to week 12, then every four weeks to week 24.

What the Study Cannot Tell You

The design carries limits the authors themselves flag. Because hypoglycemia was assessed retrospectively from clinical records, nocturnal or asymptomatic episodes without a recorded glucose value may have been missed. No formal a priori sample size calculation was performed; the 112-patient cohort reflected the availability of eligible records during the study window. Comprehensive pre-transplant clinical records were not available to the study team.

Immunosuppression was uniform in outline — tacrolimus targeted at trough levels of 10–15 ng/mL in months 1–3, prednisolone tapered from 20 mg/day to 5 mg/day by six months, plus mycophenolate mofetil 1.5 g/day — so the findings may not generalize to regimens that differ materially.

Why This Cohort Is Different

The early post-transplant period is metabolically unstable by design: surgical stress, rapidly shifting renal function, and frequent changes in immunosuppressant and steroid doses all alter insulin secretion and insulin resistance, the report notes. Both pre-transplant and post-transplant diabetes are risk factors for myocardial infarction after renal transplantation, per the studies the paper cites.

Both degludec and glargine were used in the study, which found no statistically significant differences in glycemic or renal outcomes between the two groups — a reminder that regimen choice in transplant diabetes need not be driven by differences in efficacy measured at the Kolkata center.

Funding transparency: the Cureus report does not disclose external industry funding for the retrospective analysis; the work was conducted under an ethics exemption (approval NHRTIICSEC/INV/Non-Reg/2025/005, dated April 1, 2025) from the Narayana Health ethics committee in Kolkata.

Study Limited to Transplant Recipients on Corticosteroids with Type 2 Diabetes

  • This regimen was studied in adults with pre-existing type 2 diabetes after renal transplantation on corticosteroid-based immunosuppression; patients without a transplant, with type 1 diabetes, or with active graft rejection were not part of this cohort.
  • Any blood glucose below 54 mg/dL is clinically significant hypoglycemia under the study’s definitions, and any event requiring another person’s help — carbohydrate, glucagon, or resuscitative measures — is severe and warrants immediate medical contact.

Where the Evidence Goes Next

The trajectory is clear from the numbers: nearly 92% of patients ended the 24 weeks at an HbA1c below 8%, up from a baseline average of 8.9%. What remains untested is whether degludec’s numerically lower nocturnal hypoglycemia rate — 6.7% versus 13.5% — would reach statistical significance in a larger, randomized cohort, a question this retrospective design was not built to answer.

References

  • Cureus: “Short-Term Efficacy and Safety of Basal-Bolus Insulin Regimens in Renal Transplant Recipients With Pre-existing Type 2 Diabetes Mellitus in Early Post-transplant Outpatient Settings” (2025).
  • UK Prospective Diabetes Study (UKPDS), cited in the report for progressive beta-cell loss in type 2 diabetes.
  • 59th Annual Meeting of the European Association for the Study of Diabetes (EASD), Hamburg, October 2–6, 2023 — preliminary abstract of a subset of this cohort.
  • Narayana Health Rabindranath Tagore International Institute of Cardiac Sciences Ethics Committee, Kolkata — approval NHRTIICSEC/INV/Non-Reg/2025/005.

Insulin regimens after organ transplantation must be individualized and supervised by a qualified healthcare team.

Photo of author

Health Desk

Health Desk at Archyde.

Bavuma Ruled Out of Fielding With Calf Strain; Markram to Captain South Africa